BRIEF-CalciMedica Announces Discontinuation Of Phase 2 Kourage Trial In Aki Following Independent Data Monitoring Committee Recommendation

Reuters01-28

Jan 28 (Reuters) - CalciMedica Inc CALC.O:

CALCIMEDICA ANNOUNCES DISCONTINUATION OF PHASE 2 KOURAGE TRIAL IN AKI FOLLOWING INDEPENDENT DATA MONITORING COMMITTEE RECOMMENDATION
CALCIMEDICA INC: SAFETY CONCERN WARRANTS REEVALUATION OF STUDY DESIGN, INCLUDING ENROLLMENT CRITERIA
CALCIMEDICA INC: POTENTIAL FUTURE TRIAL WITH AUXORA IN AKI TO BE EVALUATED AFTER DATA ANALYSIS
CALCIMEDICA INC - IDMC IDENTIFIES SAFETY CONCERN IN STUDY DESIGN
CALCIMEDICA INC: THERE WERE NO DEATHS IN TRIAL THAT WERE ASSESSED BY INVESTIGATORS OR CALCIMEDICA AS BEING RELATED TO STUDY DRUG

Source text: ID:nPn79FFBZa

Further company coverage: CALC.O

((Reuters.Briefs@thomsonreuters.com;))

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2606151537?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-01-28 20:05","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2606151537","market":"nz","top_or_hot":-1,"title":"BRIEF-CalciMedica Announces Discontinuation Of Phase 2 Kourage Trial In Aki Following Independent Data Monitoring Committee Recommendation","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\"><head><title>BRIEF-CalciMedica Announces Discontinuation Of Phase 2 Kourage Trial In Aki Following Independent Data Monitoring Committee Recommendation</title></head><body><p><span>Jan 28 (Reuters)</span><span> - </span>CalciMedica Inc <span>CALC.O</span>:</p><ul><li><p><a href=\"https://laohu8.com/S/CALC\">CALCIMEDICA</a> ANNOUNCES DISCONTINUATION OF PHASE 2 KOURAGE TRIAL IN AKI FOLLOWING INDEPENDENT DATA MONITORING COMMITTEE RECOMMENDATION</p></li><li><p>CALCIMEDICA INC: SAFETY CONCERN WARRANTS REEVALUATION OF STUDY DESIGN, INCLUDING ENROLLMENT CRITERIA</p></li><li><p>CALCIMEDICA INC: POTENTIAL <a href=\"https://laohu8.com/S/FUTR.UK\">FUTURE</a> TRIAL WITH AUXORA IN AKI TO BE EVALUATED AFTER DATA ANALYSIS</p></li><li><p>CALCIMEDICA INC - IDMC IDENTIFIES SAFETY CONCERN IN STUDY DESIGN</p></li><li><p>CALCIMEDICA INC: THERE WERE NO DEATHS IN TRIAL THAT WERE ASSESSED BY INVESTIGATORS OR CALCIMEDICA AS BEING RELATED TO STUDY DRUG</p></li></ul><p>Source text: <span>ID:nPn79FFBZa</span></p><p>Further company coverage: <span>CALC.O</span></p><p> ((Reuters.Briefs@thomsonreuters.com;))</p></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>BRIEF-CalciMedica Announces Discontinuation Of Phase 2 Kourage Trial In Aki Following Independent Data Monitoring Committee Recommendation</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nBRIEF-CalciMedica Announces Discontinuation Of Phase 2 Kourage Trial In Aki Following Independent Data Monitoring Committee Recommendation\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2026-01-28 20:05</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\"><head><title>BRIEF-CalciMedica Announces Discontinuation Of Phase 2 Kourage Trial In Aki Following Independent Data Monitoring Committee Recommendation</title></head><body><p><span>Jan 28 (Reuters)</span><span> - </span>CalciMedica Inc <span>CALC.O</span>:</p><ul><li><p><a href=\"https://laohu8.com/S/CALC\">CALCIMEDICA</a> ANNOUNCES DISCONTINUATION OF PHASE 2 KOURAGE TRIAL IN AKI FOLLOWING INDEPENDENT DATA MONITORING COMMITTEE RECOMMENDATION</p></li><li><p>CALCIMEDICA INC: SAFETY CONCERN WARRANTS REEVALUATION OF STUDY DESIGN, INCLUDING ENROLLMENT CRITERIA</p></li><li><p>CALCIMEDICA INC: POTENTIAL <a href=\"https://laohu8.com/S/FUTR.UK\">FUTURE</a> TRIAL WITH AUXORA IN AKI TO BE EVALUATED AFTER DATA ANALYSIS</p></li><li><p>CALCIMEDICA INC - IDMC IDENTIFIES SAFETY CONCERN IN STUDY DESIGN</p></li><li><p>CALCIMEDICA INC: THERE WERE NO DEATHS IN TRIAL THAT WERE ASSESSED BY INVESTIGATORS OR CALCIMEDICA AS BEING RELATED TO STUDY DRUG</p></li></ul><p>Source text: <span>ID:nPn79FFBZa</span></p><p>Further company coverage: <span>CALC.O</span></p><p> ((Reuters.Briefs@thomsonreuters.com;))</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4007","symbol_name":"制药","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260128:nTUA7SYRTP:1","article_id":"2606151537","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2606151537","pubTimestamp":1769601915,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"BRIEF-CalciMedica Announces Discontinuation Of Phase 2 Kourage Trial In Aki Following Independent Data Monitoring Committee RecommendationJan 28 (Reuters) - CalciMedica Inc CALC.O:CALCIMEDICA ANNOUNCE","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4007":"制药","CALC":"CALCIMEDICA"},"translate_title":"简报-CalciMedica根据独立数据监测委员会的建议宣布终止AKI 2期Kourage试验","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"CALC":0.9},"content_text":"BRIEF-CalciMedica Announces Discontinuation Of Phase 2 Kourage Trial In Aki Following Independent Data Monitoring Committee RecommendationJan 28 (Reuters) - CalciMedica Inc CALC.O:CALCIMEDICA ANNOUNCES DISCONTINUATION OF PHASE 2 KOURAGE TRIAL IN AKI FOLLOWING INDEPENDENT DATA MONITORING COMMITTEE RECOMMENDATIONCALCIMEDICA INC: SAFETY CONCERN WARRANTS REEVALUATION OF STUDY DESIGN, INCLUDING ENROLLMENT CRITERIACALCIMEDICA INC: POTENTIAL FUTURE TRIAL WITH AUXORA IN AKI TO BE EVALUATED AFTER DATA ANALYSISCALCIMEDICA INC - IDMC IDENTIFIES SAFETY CONCERN IN STUDY DESIGNCALCIMEDICA INC: THERE WERE NO DEATHS IN TRIAL THAT WERE ASSESSED BY INVESTIGATORS OR CALCIMEDICA AS BEING RELATED TO STUDY DRUGSource text: ID:nPn79FFBZaFurther company coverage: CALC.O ((Reuters.Briefs@thomsonreuters.com;))","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"symbols":[],"gpt_button":1,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.36.2","shortVersion":"4.36.2","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2606151537","isCrawlerRequest":true}